Haematologica (Jan 2007)

Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation

  • Anna Locasciulli,
  • Rosi Oneto,
  • Andrea Bacigalupo,
  • Gerard Socié,
  • Elisabeth Korthof,
  • Albert Bekassy,
  • Hubert Schrezenmeier,
  • Jakob Passweg,
  • Monika Führer

DOI
https://doi.org/10.3324/haematol.10075
Journal volume & issue
Vol. 92, no. 1

Abstract

Read online

Background and Objectives The treatment of acquired aplastic anemia (AA) is based on allogeneic bone marrow transplantation (BMT) and immunosuppressive therapy. The aim of this study was to assess the outcome of children and adults with AA treated in the last decade, and to determine whether results have improved in two sequential time periods: 1991–1996 and 1997–2002.Design and Methods We studied 2479 consecutive patients with AA, classified according to first-line treatment, BMT (n=1567) or immunosuppressive therapy (n=912), and stratified according to two sequential time periods. Analyses included variables related to the patients, disease and transplant.Results The actuarial 10-year survival was 73% and 68% for patients treated with BMT or immunosuppression, respectively (p=0.002). BMT outcome improved significantly with time (69% and 77%, p=001) for both matched sibling donor (MSD) (74% and 80%; p=0.003) and alternative donor (38% and 65% p=0.0001) transplants, and was better in children (79% versus 68%, p